Han Fei, Liu Wenbin, Xiao Hualiang, Dong Yan, Sun Lei, Mao Chengyi, Yin Li, Jiang Xiao, Ao Lin, Cui Zhihong, Cao Jia, Liu Jinyi
Institute of Toxicology, College of Preventive Medicine, Third Military Medical University.
Key Laboratory of Medical Protection for Electromagnetic Radiation, Ministry of Education of China, Chongqing 400038, PR China.
Sci Rep. 2015 Sep 2;5:13630. doi: 10.1038/srep13630.
In our previous study, we had identified SOX30 as a novel tumor suppressor that acts through direct regulation of p53 transcription in human lung cancer. Here, we sought to determine the clinical relevance of SOX30 expression in a series of surgically-resected non-small cell lung cancer (NSCLC) patients. Analysis of SOX30 expression and clinico-pathologic features reveal a significant correlation of SOX30 expression with histological type (n = 220, P = 0.008) and clinical stage (n = 220, P = 0.024). Kaplan-Meier analysis indicates an association of high SOX30 expression with better prognosis in NSCLC patients (n = 220, P = 0.007). Via multivariate Cox-regression analysis, SOX30 expression is revealed to be an independent prognostic factor for overall survival (OS) of NSCLC patients (n = 220, P = 0.014, hazard ratio (HR) = 0.816). In particular, SOX30 is a favorable and independent prognostic factor in one main subtype of NSCLC, lung adenocarcinoma (ADC) patients (n = 150, P = 0.000, HR = 0.405), but not in another main subtype of NSCLC, squamous cell carcinoma patients. Furthermore, high expression of SOX30 represents a favorable and independent factor for the prognosis of ADC patients at clinical stage II (P = 0.013), with positive lymph node (P = 0.003), at histological grade 2 (P = 0.000) or grade 3 (P = 0.025). In summary, SOX30 expression represents an important prognostic factor for survival time in ADC patients.
在我们之前的研究中，我们已将SOX30鉴定为一种新型肿瘤抑制因子，其通过直接调控人肺癌中的p53转录发挥作用。在此，我们试图确定一系列手术切除的非小细胞肺癌（NSCLC）患者中SOX30表达的临床相关性。对SOX30表达及临床病理特征的分析显示，SOX30表达与组织学类型（n = 220，P = 0.008）和临床分期（n = 220，P = 0.024）显著相关。Kaplan-Meier分析表明，NSCLC患者中SOX30高表达与较好的预后相关（n = 220，P = 0.007）。通过多变量Cox回归分析，发现SOX30表达是NSCLC患者总生存期（OS）的独立预后因素（n = 220，P = 0.014，风险比（HR）= 0.816）。特别地，SOX30是NSCLC的一种主要亚型——肺腺癌（ADC）患者（n = 150，P = 0.000，HR = 0.405）的有利且独立的预后因素，但在NSCLC的另一种主要亚型——鳞状细胞癌患者中并非如此。此外，SOX30高表达是II期临床（P = 0.013）、有阳性淋巴结（P = 0.003）、组织学2级（P = 0.000）或3级（P = 0.025）的ADC患者预后的有利且独立因素。总之，SOX30表达是ADC患者生存时间的重要预后因素。
